FDA Approves TAFINLAR — Novartis Pharmaceuticals Corporation

# FDA Approves Novartis's TAFINLAR (Dabrafenib) for Melanoma Treatment Novartis Pharmaceuticals Corporation received FDA approval for TAFINLAR (dabrafenib mesylate), an oral targeted therapy that addresses a significant market opportunity in melanoma treatment and positions the company to compete in the growing precision oncology segment. The approval of this BRAF inhibitor is expected to capture meaningful market share from existing melanoma therapies and establish a new revenue stream for Novartis in personalized cancer care.